137 related articles for article (PubMed ID: 35717732)
1. Coarse grained modelling highlights the binding differences in the two different allosteric sites of the Human Kinesin EG5 and its implications in inhibitor design.
Alexandar SP; Yennamalli RM; Ulaganathan V
Comput Biol Chem; 2022 Aug; 99():107708. PubMed ID: 35717732
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
Makala H; Ulaganathan V
J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
[TBL] [Abstract][Full Text] [Related]
3. Novel Allosteric Pathway of Eg5 Regulation Identified through Multivariate Statistical Analysis of Hydrogen-Exchange Mass Spectrometry (HX-MS) Ligand Screening Data.
Sheff JG; Farshidfar F; Bathe OF; Kopciuk K; Gentile F; Tuszynski J; Barakat K; Schriemer DC
Mol Cell Proteomics; 2017 Mar; 16(3):428-437. PubMed ID: 28062800
[TBL] [Abstract][Full Text] [Related]
4. Binding patterns of inhibitors to different pockets of kinesin Eg5.
Jia N; Zhang B; Huo Z; Qin J; Ji Q; Geng Y
Arch Biochem Biophys; 2024 Jun; 756():109998. PubMed ID: 38641233
[TBL] [Abstract][Full Text] [Related]
5. Exploring the intermediate states of ADP-ATP exchange: a simulation study on Eg5.
Zhang W
J Phys Chem B; 2011 Feb; 115(5):784-95. PubMed ID: 21192710
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
Yokoyama H; Sawada J; Katoh S; Matsuno K; Ogo N; Ishikawa Y; Hashimoto H; Fujii S; Asai A
ACS Chem Biol; 2015 Apr; 10(4):1128-36. PubMed ID: 25622007
[TBL] [Abstract][Full Text] [Related]
7. Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy.
Myers SM; Collins I
Future Med Chem; 2016; 8(4):463-89. PubMed ID: 26976726
[TBL] [Abstract][Full Text] [Related]
8. Kolaflavanone, a biflavonoid derived from medicinal plant Garcinia, is an inhibitor of mitotic kinesin Eg5.
Alrazi IMD; Ogunwa TH; Kolawole AO; Elekofehinti OO; Omotuyi OI; Miyanishi T; Maruta S
J Biochem; 2021 Dec; 170(5):611-622. PubMed ID: 34264310
[TBL] [Abstract][Full Text] [Related]
9. Lead Generation for Human Mitotic Kinesin Eg5 Using Structure-based Virtual Screening and Validation by In-vitro and Cell-based Assays.
Makala H; Alexandar SP; Nagarajan D; Mahapatra SK; Ulaganathan V
Curr Comput Aided Drug Des; 2021; 17(6):759-772. PubMed ID: 32703141
[TBL] [Abstract][Full Text] [Related]
10. Using a comprehensive approach to investigate the interaction between Kinesin-5/Eg5 and the microtubule.
Guo W; Sun S; Sanchez JE; Lopez-Hernandez AE; Ale TA; Chen J; Afrin T; Qiu W; Xie Y; Li L
Comput Struct Biotechnol J; 2022; 20():4305-4314. PubMed ID: 36051882
[TBL] [Abstract][Full Text] [Related]
11. Identifying and characterising promising small molecule inhibitors of kinesin spindle protein using ligand-based virtual screening, molecular docking, molecular dynamics and MM‑GBSA calculations.
Elseginy SA
J Comput Aided Mol Des; 2024 Apr; 38(1):16. PubMed ID: 38556596
[TBL] [Abstract][Full Text] [Related]
12. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.
Kaan HY; Ulaganathan V; Hackney DD; Kozielski F
Biochem J; 2009 Dec; 425(1):55-60. PubMed ID: 19793049
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol.
Maliga Z; Mitchison TJ
BMC Chem Biol; 2006 Feb; 6():2. PubMed ID: 16504166
[TBL] [Abstract][Full Text] [Related]
14. Structural snapshots of the kinesin-2 OSM-3 along its nucleotide cycle: implications for the ATP hydrolysis mechanism.
Varela PF; Chenon M; Velours C; Verhey KJ; Ménétrey J; Gigant B
FEBS Open Bio; 2021 Mar; 11(3):564-577. PubMed ID: 33513284
[TBL] [Abstract][Full Text] [Related]
15. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
16. Analysis of conformational motions and residue fluctuations for Escherichia coli ribose-binding protein revealed with elastic network models.
Li HY; Cao ZX; Zhao LL; Wang JH
Int J Mol Sci; 2013 May; 14(5):10552-69. PubMed ID: 23698778
[TBL] [Abstract][Full Text] [Related]
17. Microtubule cross-linking triggers the directional motility of kinesin-5.
Kapitein LC; Kwok BH; Weinger JS; Schmidt CF; Kapoor TM; Peterman EJ
J Cell Biol; 2008 Aug; 182(3):421-8. PubMed ID: 18678707
[TBL] [Abstract][Full Text] [Related]
18. Optical Control of Mitosis with a Photoswitchable Eg5 Inhibitor.
Impastato AC; Shemet A; Vepřek NA; Saper G; Hess H; Rao L; Gennerich A; Trauner D
Angew Chem Int Ed Engl; 2022 Feb; 61(9):e202115846. PubMed ID: 34958711
[TBL] [Abstract][Full Text] [Related]
19. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
20. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
